Buyback yield (TTM)
8.51%
Shareholder yield (TTM)
9.15%
5Y share count change
-33.2%
Buyback spend (TTM)
$9.13B
Cumulative buybacks
$79.06B
Key takeaways
- HCA Healthcare (HCA) repurchased about $9.13B of stock over the trailing twelve months.
- Diluted share count is down 33.2% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 92.24× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +86.9% per year over the latest 5-year window.
- TTM repurchases used about 126% of free cash flow remaining after dividends.
Dividend & buyback yield over time for HCA Healthcare (HCA)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for HCA Healthcare (HCA)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for HCA Healthcare (HCA)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for HCA Healthcare (HCA)
Latest: $10.07B
Overview
As of the 2025 fiscal year, HCA Healthcare (HCA) reported buyback spend of $10.07B – surged 66.6% year-over-year.
Over 2020–2025 (5 years), HCA Healthcare buyback spend expanded at a +86.9% compound annual rate, sustaining 2 straight years of year-over-year growth.
Between 2006 and 2025, HCA Healthcare buyback spend plunged 52.1%, falling from $21.02B to $10.07B.
2006 marks the peak buyback spend at $21.02B, with the historical low of $0.00 recorded in 1990.
HCA Healthcare Buyback Spend 2025: $10.07B
HCA Healthcare buyback spend in 2025 was $10.07B, surged 66.6% from 2024.
HCA Healthcare Buyback Spend 2024: $6.04B
2024's buyback spend for HCA Healthcare came in at $6.04B, surged 58.5% from 2023.
HCA Healthcare Buyback Spend 2023: $3.81B
HCA Healthcare posted buyback spend of $3.81B in 2023, plunged 45.6% below 2022.
HCA Healthcare Buyback Spend 2022: $7.00B
In 2022, HCA Healthcare reported buyback spend of $7.00B, declined 14.8% below 2021.
HCA Healthcare Buyback Spend 2021: $8.21B
HCA Healthcare buyback spend in 2021 was $8.21B.
See more financial history for HCA Healthcare (HCA).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $10.07B | $0.00 | $10.07B | 9.35% | 0.23B | -11.9% | |
| 2024 | $6.04B | $360.00M | $5.68B | 7.98% | 0.26B | -5.3% | |
| 2023 | $3.81B | $0.00 | $3.81B | 5.30% | 0.28B | -6.2% | |
| 2022 | $7.00B | $341.00M | $6.66B | 10.52% | 0.29B | -10.4% | |
| 2021 | $8.21B | $440.00M | $7.78B | 10.47% | 0.33B | -4.8% | |
| 2020 | $441.00M | $362.00M | $79.00M | 0.79% | 0.35B | -0.8% | |
| 2019 | $1.03B | $347.00M | $684.00M | 2.06% | 0.35B | -2.0% | |
| 2018 | $1.53B | $268.00M | $1.26B | 3.59% | 0.36B | -4.5% | |
| 2017 | $2.05B | $270.00M | $1.78B | 6.67% | 0.37B | -6.0% | |
| 2016 | $2.75B | $251.00M | $2.50B | 10.03% | 0.40B | -7.2% | |
| 2015 | $2.40B | $239.00M | $2.16B | 8.89% | 0.43B | -5.2% | |
| 2014 | $1.75B | $163.00M | $1.59B | 5.67% | 0.45B | -2.5% | |
| 2013 | $500.00M | $113.00M | $387.00M | 2.38% | 0.46B | +0.5% | |
| 2012 | $0.00 | $56.00M | −$56.00M | — | 0.46B | -7.4% | |
| 2011 | $1.50B | $26.00M | $1.48B | 15.62% | 0.50B | +13.4% | |
| 2010 | $0.00 | $32.00M | −$32.00M | — | 0.44B | +25.4% | |
| 2009 | $0.00 | $40.00M | −$40.00M | — | 0.35B | 0.0% | |
| 2008 | $0.00 | $32.00M | −$32.00M | — | 0.35B | 0.0% | |
| 2007 | $0.00 | $24.00M | −$24.00M | — | 0.35B | -15.0% | |
| 2006 | $21.02B | $324.00M | $20.69B | 158.80% | 0.41B | -8.3% | |
| 2005 | $1.86B | $0.00 | $1.86B | 14.79% | 0.45B | -7.5% | |
| 2004 | $3.11B | $0.00 | $3.11B | 23.44% | 0.48B | -5.2% | |
| 2003 | $1.11B | $0.00 | $1.11B | 7.36% | 0.51B | -2.6% | |
| 2002 | $282.00M | $0.00 | $282.00M | 1.79% | 0.52B | -2.4% | |
| 2001 | $1.51B | $0.00 | $1.51B | 9.55% | 0.54B | -3.1% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.55B | -16.9% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 0.67B | +3.3% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.65B | -2.7% | |
| 1997 | $1.08B | $0.00 | $1.08B | — | 0.66B | -2.2% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.68B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$10.07B
- 2024$6.04B
- 2023$3.81B
- 2022$7.00B
- 2021$8.21B
- 2020$441.00M
- 2019$1.03B
- 2018$1.53B
- 2017$2.05B
- 2016$2.75B
- 2015$2.40B
- 2014$1.75B
- 2013$500.00M
- 2012$0.00
- 2011$1.50B
- 2010$0.00
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$21.02B
- 2005$1.86B
- 2004$3.11B
- 2003$1.11B
- 2002$282.00M
- 2001$1.51B
- 2000$0.00
- 1999$0.00
- 1998$0.00
- 1997$1.08B
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
- 1990$0.00
Buybacks vs stock-based compensation for HCA Healthcare (HCA)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 92.24×.
Buybacks vs dividends (share of cash returned) for HCA Healthcare (HCA)
How HCA Healthcare splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as HCA Healthcare, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $7.25B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation